PISCATAWAY, N.J.--(BUSINESS WIRE)--
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it will
report its financial results for the quarter ended December 31, 2010, on
Thursday, February 17, 2011 at 4:00 pm Eastern Time (ET). The release
will be followed by a live conference call, which will begin at 5:00 pm
Eastern Time (ET) on Thursday, February 17, 2011.
All interested parties may access the call by using the following
information:
|
Domestic Dial-In Number:
|
|
(877) 561 - 2748
|
|
International Dial-In Number:
|
|
(720) 545 - 0044
|
|
Access Code:
|
|
Enzon
|
The call will also be available via live audio webcast on the Enzon
website, by going to the ‘Calendar of Events' page in the ‘Investors'
section. Listeners should go to the website at least fifteen minutes
before this event to download and install any necessary audio software.
For those unable to attend the live audio webcast, a replay will be
available beginning approximately one hour after the event.
Additionally, a telephonic rebroadcast will also be available following
the call. The rebroadcast will begin on Thursday, February 17, 2011 at
approximately 8:00 pm Eastern Time (ET) and end on Thursday, February
24, 2011 at approximately 11:59 pm Eastern Time (ET). It may be accessed
using the following information:
|
Domestic Dial-In Number:
|
|
(800) 642 - 1687
|
|
International Dial-In Number:
|
|
(706) 645 - 9291
|
|
Conference ID:
|
|
43332453
|
About Enzon
Enzon Pharmaceuticals, Inc. is a biotechnology company dedicated to the
research and development of innovative therapeutics for cancer patients
with high unmet medical needs. Enzon's drug-development programs utilize
two platforms - Customized PEGylation Linker Technology (Customized
Linker Technology®) and third-generation mRNA-targeting
agents utilizing the Locked Nucleic Acid (LNA) technology. Enzon
currently has four product candidates in clinical development and
multiple novel LNA targets in preclinical research. Enzon receives
royalty revenues from licensing arrangements with other companies
related to sales of products developed using its proprietary Customized
Linker Technology. Further information about Enzon and this press
release can be found on the Company's web site at www.enzon.com.
Argot Partners
Andrea Rabney, 212-600-1902
andrea@argotpartners.com
Source: Enzon Pharmaceuticals, Inc.
News Provided by Acquire Media
